{"id":3914,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2012-05-10","marketCap":2.9182798862457275,"name":"Phio Pharmaceuticals Corp","phone":"15087673861","outstanding":5.449999809265137,"symbol":"PHIO","website":"https://phiopharma.com/","industry":"Biotechnology"},"price":5.405025,"year":2024,"month":7,"day":9,"weekday":"Tuesday","title":"Competitive Advantages of Phio Pharmaceuticals Corp","date":"2024-07-09","url":"/posts/2024/07/09/PHIO","content":[{"section":"Strong Research and Development Capabilities","text":"Phio Pharmaceuticals Corp possesses a robust research and development (R\u0026D) department that enables them to develop innovative and effective pharmaceutical products. This gives them a competitive edge over their peers by allowing them to bring new and improved treatments to market faster."},{"section":"Advanced Technology Platforms","text":"Phio Pharmaceuticals Corp leverages advanced technology platforms in their drug discovery and development processes. These platforms enable them to optimize and accelerate various stages of pharmaceutical research, such as target identification, lead compound selection, and preclinical testing. This sophisticated technology infrastructure sets them apart from industry peers and positions them well for rapid product development."},{"section":"Strategic Partnerships","text":"Phio Pharmaceuticals Corp has established strategic partnerships with leading academic institutions, research organizations, and pharmaceutical companies. These collaborations provide access to cutting-edge scientific knowledge, expertise, and resources that enhance their research capabilities. By leveraging these partnerships, Phio Pharmaceuticals Corp gains a competitive advantage in terms of access to novel research opportunities and potential collaborations for drug discovery and development."},{"section":"Strong Intellectual Property Portfolio","text":"Phio Pharmaceuticals Corp possesses a significant intellectual property (IP) portfolio that includes patents, trade secrets, and proprietary technologies. This IP protection safeguards their novel discoveries, processes, and formulations, preventing competitors from replicating their advancements. This exclusivity provides Phio Pharmaceuticals Corp with a competitive advantage in terms of market exclusivity, pricing power, and the ability to attract licensing and partnership opportunities."},{"section":"Experienced Management Team","text":"Phio Pharmaceuticals Corp is led by an experienced and skilled management team with a proven track record in the pharmaceutical industry. This team possesses deep industry knowledge, strategic vision, and operational expertise, enabling them to make informed decisions and navigate challenges effectively. The strong leadership at Phio Pharmaceuticals Corp sets them apart from their industry peers and positions them for sustainable growth and success."},{"section":"Focus on Targeted Therapies","text":"Phio Pharmaceuticals Corp focuses on the development of targeted therapies, which are designed to selectively address specific molecular targets associated with diseases. This approach allows them to deliver more personalized and effective treatments to patients, minimizing side effects and enhancing therapeutic outcomes. Their focus on targeted therapies distinguishes them from competitors who may have a broader product portfolio."},{"section":"Commitment to Clinical Excellence","text":"Phio Pharmaceuticals Corp maintains a strong commitment to clinical excellence throughout their drug development process. They adhere to rigorous quality standards, conduct comprehensive clinical trials, and prioritize patient safety and efficacy. This commitment differentiates them from industry peers and instills confidence in healthcare providers, regulators, and patients regarding the reliability and effectiveness of their pharmaceutical products."},{"section":"Agility and Adaptability","text":"Phio Pharmaceuticals Corp demonstrates agility and adaptability in responding to evolving market dynamics, scientific advancements, and regulatory changes. This enables them to quickly capitalize on emerging opportunities, address new challenges, and optimize their operations. Their ability to adapt swiftly positions them ahead of industry peers and ensures they remain competitive in a rapidly changing pharmaceutical landscape."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1720440000,"headline":"Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762","id":128625275,"image":"https://media.zenfs.com/en/newsfile_64/8f29a3610b12f0614f3455f8284cd4d1","symbol":"PHIO","publisher":"Yahoo","summary":"Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the addition of the University of Pittsburgh Medical Center (UPMC) Department of Dermatology in Pittsburgh, PA as a clinical trial site ..","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-addition-clinical-120000931.html"},{"category":"company","date":1720180800,"headline":"Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds","id":128597834,"image":"https://media.zenfs.com/en/newsfile_64/0271fed9d688b6857bca210a5a7b5e07","symbol":"PHIO","publisher":"Yahoo","summary":"Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock.About Phio Pharmaceuticals Corp.Phio Pharmaceuti","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-terminates-share-purchase-120000305.html"},{"category":"company","date":1719935100,"headline":"Phio Pharmaceuticals Announces Reverse Stock Split","id":128557489,"image":"https://media.zenfs.com/en/newsfile_64/0eb445645823e4320c96d36ca1a233c4","symbol":"PHIO","publisher":"Yahoo","summary":"Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the \"Company\"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-9. The reverse stock split will become effective at 12:01 a.m. ...","url":"https://finance.yahoo.com/news/phio-pharmaceuticals-announces-reverse-stock-154500455.html"}]}